Sagimet furnishes updated investor presentation on NASH, acne, cancer pipeline

Sagimet Biosciences Inc.

Filed updated slide deck under Item 7.01 for use in investor meetings.
Presentation targets metabolic dysfunction therapies for NASH, acne, and cancer.
No specific financial or clinical data from the deck was disclosed in the 8-K.

item 7.01 item 9.01

Sagimet Biosciences Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-110654

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.